HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Wei-Min Zhao Selected Research

periplocoside E

9/2006Periplocoside E inhibits experimental allergic encephalomyelitis by suppressing interleukin 12-dependent CCR5 expression and interferon-gamma-dependent CXCR3 expression in T lymphocytes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Wei-Min Zhao Research Topics

Disease

3Ischemic Stroke
03/2021 - 11/2016
3Neoplasms (Cancer)
08/2008 - 08/2004
3Breast Neoplasms (Breast Cancer)
06/2005 - 08/2004
2Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
03/2021 - 11/2016
2Inflammation (Inflammations)
04/2017 - 09/2006
2Hypersensitivity (Allergy)
02/2006 - 10/2002
1Cerebral Infarction
03/2021
1Ischemia
03/2021
1Edema (Dropsy)
01/2021
1Autoimmune Diseases (Autoimmune Disease)
01/2021
1Rheumatoid Arthritis
01/2021
1Arthritis (Polyarthritis)
01/2021
1Colorectal Neoplasms (Colorectal Cancer)
10/2017
1Brain Infarction
11/2016
1Glioma (Gliomas)
01/2012
1Colonic Neoplasms (Colon Cancer)
01/2012
1Lymphatic Metastasis
01/2012
1Neoplasm Metastasis (Metastasis)
01/2012
1Chronic Bronchitis
06/2010
1Wounds and Injuries (Trauma)
06/2010
1Nasopharyngeal Carcinoma
08/2008
1Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
09/2006
1Multiple Sclerosis
09/2006
1Adenocarcinoma
06/2005
1Ovarian Neoplasms (Ovarian Cancer)
08/2004
1Delayed Hypersensitivity (Hypersensitivity, Type IV)
10/2002

Drug/Important Bio-Agent (IBA)

3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
08/2008 - 08/2004
2DinitrofluorobenzeneIBA
01/2021 - 10/2002
2GlycosidesIBA
01/2021 - 06/2010
2Epidermal Growth Factor (EGF)IBA
06/2005 - 08/2004
128-O-caffeoyl betulinIBA
03/2021
1salicylhydroxamic acid (SHAM)IBA
03/2021
1Acetylcholine (Acetylcholine Chloride)FDA Link
03/2021
1Aminobutyrates (Aminobutyric Acid)IBA
03/2021
1Carnitine (L-Carnitine)FDA LinkGeneric
03/2021
1Glutathione (Reduced Glutathione)IBA
03/2021
1Neurotransmitter Agents (Neurotransmitter)IBA
03/2021
1Lactic Acid (Lactate)FDA LinkGeneric
03/2021
1Succinic Acid (Succinate)IBA
03/2021
1CytokinesIBA
01/2021
1CarrageenanIBA
01/2021
1Interleukin-17 (Interleukin 17)IBA
01/2021
1Cardiac GlycosidesIBA
01/2021
1Beclin-1IBA
10/2017
1rosmarinic acid n-butyl esterIBA
04/2017
1Pharmaceutical PreparationsIBA
04/2017
1EstersIBA
11/2016
1antineoplaston A10 (A 10)IBA
11/2016
1TriterpenesIBA
11/2016
1Smoothened ReceptorIBA
01/2012
1ParaffinIBA
01/2012
1Proteins (Proteins, Gene)FDA Link
01/2012
1Transcription Factors (Transcription Factor)IBA
01/2012
1Biomarkers (Surrogate Marker)IBA
01/2012
1spiroketalIBA
06/2010
1breynin IIBA
06/2010
1breyniaionoside EIBA
06/2010
1SulfurIBA
06/2010
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
08/2008
1staurosporine aglycone (K252a)IBA
08/2008
1Therapeutic UsesIBA
09/2006
1InterleukinsIBA
09/2006
1periplocoside EIBA
09/2006
1Interferon-gamma (Interferon, gamma)IBA
09/2006
1OvalbuminIBA
02/2006
1AntigensIBA
02/2006
1Growth Factor ReceptorsIBA
06/2005
1Tyrosine Kinase InhibitorsIBA
06/2005
1verticillinsIBA
06/2005
1Tyrosine (L-Tyrosine)FDA Link
04/2005
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2005
1Indicators and Reagents (Reagents)IBA
10/2002

Therapy/Procedure

2Chinese Traditional Medicine (Traditional Chinese Medicine)
01/2021 - 06/2010
2Therapeutics
08/2008 - 08/2004
1Oral Administration
01/2021
1Chemoprevention
08/2008